Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kaken to Codevelop TWOCELLS’ Cell Therapy in Japan
Kaken Pharmaceutical said on June 2 that it will jointly develop gMSC1, a cell therapy originated by TWOCELLS, a spinoff of Hiroshima University, for orthopedic indications in Japan. The two companies entered into a license agreement, under which Kaken will…
To read the full story
Related Article
- Chugai, TWOCELLS End Knee Chondrogenesis Cell Therapy Deal
April 14, 2023
- Chugai/TWOCELLS Complete PIII Enrollment for Knee Chondrogenesis Cell Medicine
October 28, 2021
- Hiroshima Univ. Spinoff Initiates PIII Study for Regenerative Cellular Medicine for Chondrogenesis in Knee
December 1, 2017
- Chugai, Hiroshima Univ. Spinoff Join Hands in Cartilage Regeneration
April 26, 2016
BUSINESS
- Takeda Files Japan NDA for Narcolepsy Drug Oveporexton
March 5, 2026
- Kyowa Kirin Sticks to Long-Term Targets despite Rocatinlimab Setback
March 5, 2026
- Ono Partners with Congruence on Neurology, Immunology Drug Discovery
March 5, 2026
- Nxera Files for Daridorexant Approval in South Korea
March 5, 2026
- Sawai Prevails in Patent Suit against Viatris over Amitiza Generic
March 5, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…